Table 2.
Clinical outcomes at the beginning and the end of the study and the within-group change with the corresponding confidence intervals (P value refers to the significance level for the between-group difference).
|
|
Control group (n=46) | Telemonitoring group (n=47) |
|
|
||||
| Begin | End | Change (95% Cl) | Begin | End | Change (95% Cl) | Effect size (95% Cl) | P value | |
| NT-proBNP (ng/l), median (interquartile range)a | 1338 (474-2974) |
731 (368-2408) |
-50 (-831 to 260) |
2347 (998-3568) |
1014 (609-2631) |
-198 (-1921 to 170) |
Median difference -148 | .256 |
| LVEF (%), mean (SD) | 28.6 (5.0) | 32.8 (8.2) | 4.2 (1.8-6.5) |
27.3 (4.9) | 32.4 (9.8) | 5.0 (1.8-8.1) |
β=-.04 (-3.658 to 3.743) |
.982 |
| EHFSBS score, mean (SD) | 27.9 (6.5) | 24.1 (8.3) | -3.8 (-5.4 to -2.1) |
27.6 (6.8) | 22.6 (6.9) | -5.0 (-7.1 to -3.0) |
β=-1.320 (-3.842 to 1.184) |
.298 |
| Serum creatinine (μmol/L), median (interquartile range; proportionb)a | 88.0 (78.0-121.0; 0.60) |
92.0 (84.0-115.0; 0.57) |
2.4 (-2.5 to 6.5) |
92.5 (83.8-105.3; 0.67) |
95.0 (83.5-112.3; 0.57) |
3.5 (-1.0 to 9.0) |
Median difference 0.9 | .435 |
| Serum potassium (mmol/L), mean (SD; proportionb) | 4.2 (0.3; 0.98) | 4.2 (0.4; 0.98) | -0.06 (-0.18 to 0.05) |
4.3 (0.4; 0.94) | 4.2 (0.4; 1.0) | -0.1 (-0.3 to 0.01) |
β=.008 (-0.141 to 0.156) |
.918 |
| Serum sodium (mmol/L), mean (SD; proportionb) | 140.2 (3.0; 0.96) | 140.4 (3.4; 0.85) | 0.2 (-0.7 to 1.1) |
139.6 (3.0; 0.89) | 140.7 (2.5; 0.96) | 1.0 (0.2-1.8) |
β=-.535 (-1.592 to 0.523) |
.318 |
aNon-parametric test.
bProportion of patients whose values were within reference interval.